[1]郭树龙,张久君.相对低剂量甲泼尼龙联合99Tc-MDP治疗老年Graves眼病的疗效观察[J].国际放射医学核医学杂志,2009,33(5):287-290.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.010]
　GUO Shu-long,ZHA NG Jiu-jun.Efficacy of combined 99Tc-methylenediphosphonate and lower-dose meth ylprednisolone in the treatment of old patients with moderate-to-severe Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(5):287-290.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.010]
点击复制

相对低剂量甲泼尼龙联合99Tc-MDP治疗老年Graves眼病的疗效观察(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
33
期数:
2009年第5期
页码:
287-290
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Efficacy of combined 99Tc-methylenediphosphonate and lower-dose meth ylprednisolone in the treatment of old patients with moderate-to-severe Graves ophthalmopathy
作者:
郭树龙1;  张久君2
1. 福建医科大学附属泉州第一医院内分泌科, 362000;
2. 福建医科大学附属泉州第一医院核医学科, 362000
Author(s):
GUO Shu-long1;  ZHA NG Jiu-jun2
1. Department of Endocrinalogy, the First Hospital of Quanzhou, Fujian Medical University, Fujian Quanzhou 362000, China;
2. Department of Nuclear Medicine, the First Hospital of Quanzhou, Fujian Medical University, Fujian Quanzhou 362000, China
关键词:
Graves眼病; 99m锝美罗酸盐; 甲泼尼龙; 药物疗法; 老年人
Keywords:
Graves ophthalmopathy; Technetium Tc 99m medronate; Methy lpredniselone; Drug therapy; Aged
DOI:
10.3760/cnla.j.issn.1673-4114.2009.05.010
摘要:
目的 评价相对低剂量甲泼尼龙短程疗法联合99Tc-亚甲基二膦酸盐(99Tc-MDP)治疗老年活动性中重度Graves眼病(GO)的临床疗效及安全性。方法 24例老年活动性中重度GO患者先配对后随机分人对照组及试验组各12例。对照组应用常规大剂量甲泼尼龙间断静脉短程冲击治疗,累积剂量达800~1200 mg。试验组应用相对低剂量甲泼尼龙(累积剂量为300~480 mg)联合99Tc-MDP的治疗方案。治疗前及开始治疗后每1~4周进行定期随访观察,并根据眼病临床活动性评分及美国甲状腺协会提出的甲状腺相关眼病分度分级标准评定眼部病情变化,同时监测治疗后的不良反应。应用Ridit检验进行统计分析,比较两组疗效。结果 试验组10例患者有效,对照组6例患者有效,两组的疗效有统计学差异(t=2.121,P<0.05)。对照组的不良反应明显增多,主要体现于消化道症状,引起或加重水钠潴留与糖代谢紊乱。结论 对于老年活动性中重度GO应用相对低剂量甲泼尼龙短程疗法联合99Tc-MDP是一种临床疗效及安全性较好的治疗方案。
Abstract:
Objective To assess the efficacy and safety of combined 99Tc-methylenediphosphonate(99Tc-MDP)and lower-dose methylprednisolone in the treatment of old patients with active moderate-to-severe Graves ophthalmopathy.Methods Twenty-four old patients with active moderate-to-severe Graves ophthalmopathy were randomly divided into two groups,that were methylprednisolone group(control group)and combination of 99Tc-MDP and methylprednisolone group(experimental group).The two groups were similar in age,sex,duration and severity of ophthahnopathy.Patients in control group were treated with intravenous high-dose methylprednisolone pulse therapy(cumulative dose of 800~1200 mg).experimental group were treated with combination therapy of 99Tc-MDP and lower-dose methylprednisolone(cumulative dose of 300~480 mg).At 12-week follow-up,therapeutic outcome was assessed by the change in clinical activity score and severity classified using Americom Thyroid Association of thyroid-associated ophthalmopathy indexing classification stcmdard.The adverse effects were observed and recorded in all patients.Results The remarkably effective outcome was observed in 6/12(50.0%)cases in control group and 10/12(83.3%)cases in experimental group.There were significant differences in the degree of improvements in ocular involvements.Less frequent and severe adverse effects were observed with the addition of 99Tc-MDP to lower-dose methylprednisolone therapy.Conclusion A combination of 99Tc-MDP and lower-dose methylprednisolone may be better tolerated and more effective than high-dose ophthalmopathy.

参考文献/References:

[1] Khoo TK,Bahn RS.Pathogenesis of Graves’ ophthalmopathy:the role of autoantibodies.Thyroid,2007,17(10):1013-1018.
[2] Gianoukakis AG,Khadavi N,Smith TJ.Cytokines,Graves’disease,and thyroid-associated ophthalmopathy.Thyroid,2008,18(9):953-958.
[3] Nowak M,Wielkoszyński T,Kos-Kud(i)a B,et al.The blood concentration of intercellular adhesion molecule-1(sICAM-1)and vascular cell adhesion molecule-1(sVCAM-1)in patients with activethyroid-associated orbitopathy before and after methylprednis olone treatment.Endokrynol Pol,2007,58(6):487-491.
[4] Kahaly GJ,Pitz S,Hommel G,et al.Randomized,single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy.J Clin Endocriuol Metab,2005,90(9):5234-5240.
[5] Kubo T,Shimizu J,Furujo M,et al.An infant case of Graves’disease with ophthalmopathy.Endocr J,2005,52(5):647-650.
[6] Marinó M,Morabito E,Brunetto MR,et al.Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy.Thyroid,2004,14(5):403-406.
[7] Gursoy A,Cesur M,Erdogan MF,et al.New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves’ ophthalmopathy.Endocrine,2006,29(3):513-516.
[8] Owecki M,Sowinski J.Acute myocardial infarction during high-dose methylprednisolone therapy for Graves’ ophthalmopathy.Pharm World Sci,2006,28(2):73-75.
[9] 穆荣,陈适,栗占国,等.99mTc-亚甲基二膦酸盐在类风湿关节炎的疗效及其对炎性细胞因子的抑制作用.中华风湿病学杂志,2004,8(1):39-41.
[10] Krassas GE,Perros P.Prevention of thyroid aasociated-ophthalmopathy in children and adults:current views and management of preventable risk factors.Pediatr Endocrinol Rev,2007,4(3):218-224.

相似文献/References:

[1]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
　Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[2]苏丹,赵水喜.甲状腺相关眼病的放射治疗进展[J].国际放射医学核医学杂志,2014,38(2):126.[doi:10.3760/cma.j.issn.1673-4114.2014.02.012]
　Su Dan,Zhao Shuixi.The development of radiotherapy for thyroid associated ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):126.[doi:10.3760/cma.j.issn.1673-4114.2014.02.012]
[3]李欢欢,李素平,游金辉.小细胞肺癌伴副肿瘤综合征患者骨显像示肌肉摄取一例[J].国际放射医学核医学杂志,2014,38(2):140.[doi:10.3760/cma.j.issn.1673-4114.2014.02.016]
[4]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
　WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[5]薛秀青,苏成海.99Tc-亚甲基二膦酸盐的临床应用研究进展[J].国际放射医学核医学杂志,2010,34(5):285.[doi:10.3760/cma.j.issn.1673-4114.2010.05.008]
　XUE Xiu-qing,SU Cheng-hai.Progress of 99Tc-methylenediphosphonate in clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(5):285.[doi:10.3760/cma.j.issn.1673-4114.2010.05.008]
[6]刘道佳,唐明灯,林端瑜,等.99Tcm-MDP全身骨显像、99Tcm-MDP SPECT-CT和18F-FDG SPECT-CT探测脊柱转移瘤的比较[J].国际放射医学核医学杂志,2011,35(2):89.[doi:10.3760/cma.j.issn.1673-4114.2011.02.006]
　LIU Dao-jia,TANG Ming-deng,LIN Duan-yu,et al.Comparision of the value of 99Tcm-MDP bone scintigraphy, 99Tcm-MDP SPECT-CT and 18F-FDG SPECT-CT in detecting bone metastases of spine[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):89.[doi:10.3760/cma.j.issn.1673-4114.2011.02.006]
[7]王任飞,谭建,张桂芝,等.131I治疗对Graves眼病转归的影响[J].国际放射医学核医学杂志,2011,35(4):223.[doi:10.3760/cma.j.issn.1673-4114.2011.04.007]
　WANG Ren-fei,TAN Jian,ZHANG Gui-zhi,et al.Effect of 131I therapy on outcomes of Graves’ ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):223.[doi:10.3760/cma.j.issn.1673-4114.2011.04.007]
[8]段炼,陆克义,陈霞,等.131I治疗Graves病对甲状腺相关眼病转归的相关因素分析[J].国际放射医学核医学杂志,2011,35(4):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
　DUAN Lian,LU Ke-yi,CHEN Xia,et al.Related factors of thyroid-associated ophthalmopathy in patents with Graves’ disease after 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
[9]王渊恺,袁杰,张光明,等.鼻咽癌在全身骨显像鼻部感兴趣区放射性异常的分析[J].国际放射医学核医学杂志,2011,35(1):20.[doi:10.3760/cma.j.issn.1673-4114.2011.01.006]
　WANG Yuan-kai,YUAN Jie,ZHANG Guang-ming,et al.Study on nasal radioactive anomalies of nasopharyngeal carcinoma in bone imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):20.[doi:10.3760/cma.j.issn.1673-4114.2011.01.006]
[10]徐海青,段俊,吴边.全身骨显像诊断前列腺癌骨转移与PSA水平及病理分级的相关性研究[J].国际放射医学核医学杂志,2011,35(1):34.[doi:10.3760/cma.j.issn.1673-4114.2011.01.010]
　XU Hai-qing,DUAN Jun,WU Bian.Study of relationship between the bone imaging, level of PSA and pathology grade in diagnosis of prostate carcinoma bone metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):34.[doi:10.3760/cma.j.issn.1673-4114.2011.01.010]

备注/Memo

备注/Memo:
收稿日期:2009-04-29。
通讯作者:郭树龙(E-mail:guosulon@pub2.qz.fj.cn)
更新日期/Last Update: 1900-01-01